Stockreport

NewLink Genetics Presents Encouraging Phase 2 Results for NLG207 in Ovarian Cancer at AACR 2019

NEWLINK GENETICS  (NLNK) 
Last newlink genetics earnings: 2/28 09:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.linkp.com/investor-relations
PDF AMES, Iowa, April 02, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced results from a Phase 2 study of NLG207, a nanoparticle formul [Read more]